Hepatitis C Virus (HCV) Antibody
The hepatitis C virus or HCV is an infectious virus that affects the liver. HCV is a bloodborne virus and is transmitted in various ways, including sexual contact, blood to blood contact, sharing drug needles, and before 1990 through blood or blood product transfusion. HCV infected patients have a higher risk of liver cirrhosis and liver cancer. Symptoms of infection are fatigue, abdominal discomfort, loss of appetite, and flu-like symptoms; however, the majority of patients infected with the hepatitis C virus have little to no warning symptoms, especially in the acute phase. The HCV infection if left untreated will develop into acute phase hepatitis, which is typically within the first six months following primary infection. Diagnosis is rarely made during this time frame.
When the infection is present for greater than six months, it is known as chronic phase hepatitis. Symptoms may or may not be present in chronic hepatitis, but if left untreated, scarring of the liver will likely occur over time and the risk for liver cancer increases. The diagnosis of chronic hepatitis is frequently made accidentally when routine laboratory tests are performed. Liver enzymes may be slightly elevated at this point. Approximately one-third of all patients who are not treated will acquire liver cirrhosis within 20 years. Once cirrhosis occurs, symptoms develop and liver enzymes may increase more significantly. Serological hepatitis testing is important in diagnosing patients and protecting blood recipients from infected blood products. Hepatitis C antibody testing, when positive, is confirmed by HCV PCR to determine if the infection is in active status.
- As an aid in diagnosis of hepatitis C infection
- Assess exposure to hepatitis C virus infection
- Blood Donor screening for hepatitis C virus infection
Increased in:
- Acute hepatitis C
- Chronic hepatitis C
- Blood donors infected with hepatitis C
Results should be interpreted with consideration of all clinical and laboratory findings. CDC recommendations are that HCV infection (positive results by EIA) should be evaluated by an HCV RNA molecular assay to rule out active infection. It is also recommended that genotyping should be performed to determine duration and prediction of therapy used. A third generation of HCV antibody assays that uses specific recombinant antigens to HCV have high sensitivity and specificity of 99%. RIBA assay should be used only if HCV RNA molecular assay (viremia) is negative to confirm false positive antibody results to HCV, or to confirm a viral clearance.
Negative (Non-reactive)
Enzyme immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA).
Serum (SST), plasma (EDTA).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- J Infect Dis. 2011 Sep 15;204(6):825-31. [PMID: 21849279]
- Hepatology. 1997 Sep;26(3 Suppl 1):43S-47S. [PMID: 9305663]
- J Clin Microbiol. 2008 Dec;46(12):3919-23. [PMID: 18945839]
- Clin Liver Dis. 1997 Nov;1(3):543-57, vi. [PMID: 15560057]
- Clin Chem. 2003;49:479. [PMID: 12600961]
- Clin Chem. 2003;49:940. [PMID: 12765991]
- Stevens, CD. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company (2010).
- Burtis C, Ashwood E, and Bruns D. Fundamentals of Clinical Chemistry. St. Louis: Saunders (2008).